- Home
- FUND vs LYEL Comparison
FUND vs LYEL Comparison
Compare FUND & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUND
- LYEL
- Stock Information
- Founded
- FUND 1988
- LYEL 2018
- Country
- FUND Canada
- LYEL United States
- Employees
- FUND N/A
- LYEL N/A
- Industry
- FUND Investment Managers
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- FUND Finance
- LYEL Health Care
- Exchange
- FUND Nasdaq
- LYEL Nasdaq
- Market Cap
- FUND 228.2M
- LYEL 203.9M
- IPO Year
- FUND N/A
- LYEL 2021
- Fundamental
- Price
- FUND $7.56
- LYEL $0.70
- Analyst Decision
- FUND
- LYEL Sell
- Analyst Count
- FUND 0
- LYEL 2
- Target Price
- FUND N/A
- LYEL $1.00
- AVG Volume (30 Days)
- FUND 32.5K
- LYEL 1.3M
- Earning Date
- FUND 01-01-0001
- LYEL 03-03-2025
- Dividend Yield
- FUND 6.64%
- LYEL N/A
- EPS Growth
- FUND N/A
- LYEL N/A
- EPS
- FUND 0.93
- LYEL N/A
- Revenue
- FUND N/A
- LYEL $63,000.00
- Revenue This Year
- FUND N/A
- LYEL N/A
- Revenue Next Year
- FUND N/A
- LYEL N/A
- P/E Ratio
- FUND $8.33
- LYEL N/A
- Revenue Growth
- FUND N/A
- LYEL N/A
- 52 Week Low
- FUND $6.75
- LYEL $0.51
- 52 Week High
- FUND $8.47
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- FUND 43.30
- LYEL 64.48
- Support Level
- FUND $7.65
- LYEL $0.57
- Resistance Level
- FUND $7.79
- LYEL $0.63
- Average True Range (ATR)
- FUND 0.09
- LYEL 0.05
- MACD
- FUND -0.01
- LYEL 0.02
- Stochastic Oscillator
- FUND 12.96
- LYEL 87.86
About FUND Sprott Focus Trust Inc.
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.